Atea Pharmaceuticals Inc AT-527 Clinical Data Update Call Transcript
Good morning, ladies and gentlemen, and welcome to the Atea Pharmaceuticals A2 -- AT-527 Clinical Update Conference Call. (Operator Instructions) I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Please proceed.
Thank you, operator. Good morning, everyone, and welcome to Atea Pharmaceuticals AT-527 Clinical Update Conference Call.
This morning, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website at iratteapharma.com.
With me today from Atea are Dr. Jean-Pierre Sommadossi, Founder and CEO; Dr. Janet Hammond, Chief Development Officer; John Vavricka, Chief Commercial Officer; and Andrea Corcoran, CFO. They will all be available for the Q&A portion of today's call.
Before we begin the call,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |